蒲参胶囊联合瑞舒伐他汀钙治疗冠心病合并混合型高脂血症的疗效观察

Effect Observation of Pushen Capsules Combined with Rosuvastatin Calcium in the Treatment of Coronary Heart Disease in Patients with Combined Hyperlipidemia

目的观察蒲参胶囊联合瑞舒伐他汀钙治疗冠心病合并混合型高脂血症的疗效和安全性。方法将冠心病合并混合型高脂血症患者60例随机分为性别、年龄、血脂等各指标水平匹配的A、B组,其中A组30例,每晚口服10mg瑞舒伐他汀钙,每日加服蒲参胶囊;B组30例,每晚口服10mg瑞舒伐他汀钙。两组均给予常规抗血小板、扩血管等冠心病基础用药,观察治疗4周和8周后血脂水平的变化及药物相关不良反应,每周记录心肌缺血事件发作次数、每次持续时间,并常规行心电图检查。结果治疗4周、8周后,A组三酰甘油(TG)、脂蛋白(a)〔Lp(a)〕、极低密度脂蛋白胆固醇(VLDL-C)水平明显低于B组,高密度脂蛋白胆固醇(HDL-C)水平明显高于B组,差异均有统计学意义(P<0.05);总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平与B组比较,差异无统计学意义(P>0.05)。A组心肌缺血事件发作次数较B组减少、持续时间较B组缩短,差异均有统计学意义(P<0.05)。两组治疗后心电图疗效比较,差异均有统计学意义(P<0.05)。结论蒲参胶囊联合瑞舒伐他汀钙治疗冠心病合并混合型高脂血症较单独应用瑞舒伐他汀效果更佳。

Objective To evaluate the effectiveness and safety about Pushen capsule combined with Rosuvastatin in the treatment of coronary heart disease and combined hyperlipidemia patients. Methods The patients with coronary heart disease and hyperlipidemia were randomly divided into 60 cases of sex, age, blood lipid indexes level matching A, group B, group A 30 cases, 10mg QN rosuvastatin, daily with Pushen capsules; 30 patients in group B, lOmg QN rosuvastatin calcium. The two groups were given conventional antiplatelet agents, vasodilator coronary heart disease based medication, treatment related adverse reactions of drugs and change of 4 weeks and 8 weeks after lipid levels, weekly record of myocardial ischemia attack frequency, duration time, and routine electrocardiogram. Results 4 weeks, 8 weeks after the treatment, A group of three triacylglycerol （TG）, lipoprotein （a） [Lp （a）], very low density lipoprotein cholesterol （VLDL- C） levels were significantly ＂lower than that in B group, high density lipoprotein cholesterol （HDL - C） levels were significantly higher than that in B group, the differences were statistically significant （ P 〈 0. 05 ） ; total cholesterol （ TC ） , low density lipoprotein cholesterol （ LDL - C） and compared with the B group, no significant difference （P 〉 0. 05 ）. A group myocardial ischemia attack times than in the B group than in B group decreased duration shortened, the differences were statistically significant （P 〈 0.05）. Comparison of ECG of two groups after treatment, the differences were statistically significant （P 〈 0. 05）. Conclusion Pushen capsule combind with Rosuvastatin has an excellent clinical efficacy in treating patients with coronary heart disease and combined hyperlipidemia and doesn＇t increasing drugrelated adverse reactions.